Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Pulmonary Arterial Hypertension Global Api Manufacturers Marketed And Phase Iii Drugs Landscape

"Pulmonary Arterial Hypertension - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020" report by DelveInsight offers comprehensive insights on marketed and Phase III products for Pulmonary Arterial Hypertension. The marketed products information covers their product details, patents (US & EU), historical and forecasted sales till 2023. It further provides the marketed products API manufacturer details for United States, Europe, China, and India. The report also covers the emerging Phase III pipeline assets for Pulmonary Arterial Hypertension including their detailed product profiles.


Additionally, the report also highlights the future competitive landscape for Pulmonary Arterial Hypertension therapeutics. Depending on information availability comprehensive coverage of the following for Pulmonary Arterial Hypertension marketed products for Pulmonary Arterial Hypertension descriptive marketed product profiles for Pulmonary Arterial Hypertension including (but not limited to) drug description, regulatory milestones, product development and R&D activities encompassing clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Also provided are the historical and forecasted global sales till 2023 for each product.


Global API Manufacturers of marketed products for Pulmonary Arterial Hypertension coverage of API manufacturers for Pulmonary Arterial Hypertension marketed products spanning across United States, Europe, China and India. The manufacturers details include manufacturers name along with their location Emerging Phase III products for Pulmonary Arterial Hypertension descriptive Phase III product profiles for Pulmonary Arterial Hypertension including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Also their forecasted global sales are provided till 2023.

Report Methodology 

The report provides insights into: 

  • Detailed description of the indication including causes, symptoms, pathophysiology, diagnosis and treatment
  • Comparative analysis of the marketed and emerging products 
  • Detailed profiles for the marketed therapies available including mechanism of action, dosage and administration regulatory milestones, other development activities 
  • Global sales of the marketed therapies from 2012-2023 is covered in the report
  • Global API Manufacturers for marketed therapies are provided across United States, Europe, China and India
  • List of emerging therapies with product name, company, stage of development, indication, route of administration and molecule type is also provided  

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third party sources, etc.


Pulmonary Arterial Hypertension Analytical Perspective by DelveInsight

  • In-depth Pulmonary Arterial Hypertension Commercial Assessment of Marketed Products 

This report provides an in-depth commercial assessment of marketed products, which comprises the details of collaborations, licensing, acquisition - deal value trends, patent and global sales.


  • Pulmonary Arterial Hypertension Clinical Assessment of Emerging Products

The report comprises of comparative clinical assessment of products by development stage, route of administration and molecule type across this indication.


Scope of the report

  • The Pulmonary Arterial Hypertension report provides a comprehensive understanding of Pulmonary Arterial Hypertension marketed and emerging (Phase III) products
  • Access to API manufacturers details for Pulmonary Arterial Hypertension marketed drugs to devise API procurement strategy for generic development
  • Plan developmental timelines around marketed drug patents for the major markets- US and EU
  • Understand current and future growth of marketed Pulmonary Arterial Hypertension therapeutics through their historical and forecasted sales
  • Identify and analyze future sales trends of emerging Phase III Pulmonary Arterial Hypertension therapeutics through their forecasted sales
  • Identify the products attributes and use it for target finding, drug repurposing, and precision medicine
  • Identify and plan ahead for prospective emerging players and their products for Pulmonary Arterial Hypertension


Report highlights

  • In the coming years, the Pulmonary Arterial Hypertension market is set to change due to the extensive research in this filed, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Arterial Hypertension R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • There are many companies involved in developing therapies for Pulmonary Arterial Hypertension. Launch of emerging therapies of Pulmonary Arterial Hypertension will significantly impact the market.
  • A better understanding of target mechanism will also contribute to the development of novel therapeutics for Pulmonary Arterial Hypertension.
  • Our in-depth analysis of the marketed and late-stage pipeline assets comparative analysis of the products. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.


Key Questions

  • What are the current treatment options available based on the Pulmonary Arterial Hypertension?
  • How many companies are developing therapies for Pulmonary Arterial Hypertension?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for Pulmonary Arterial Hypertension to treat disease condition?
  • How many emerging therapies are in late stage of development for Pulmonary Arterial Hypertension?
  • What is the trend of historical and forecasted sales of the marketed products from the period 2012-2023?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pulmonary Arterial Hypertension therapies? 
  • Which are the API manufacturers across United States, Europe, China and India for the marketed therapies?
  • How many patents are granted to the marketed therapies of Pulmonary Arterial Hypertension?
  • How late-stage emerging therapies are distinguished on the basis of their mechanism of action, route of administration and molecule type? 

1. Report Introduction

2. Pulmonary Arterial Hypertension

2.1. Pulmonary Arterial Hypertension Symptoms

2.2. Pulmonary Arterial Hypertension Causes  

2.3. Pulmonary Arterial Hypertension Types 

2.4. Pulmonary Arterial Hypertension Risk Factors / Complications

2.5. Pulmonary Arterial Hypertension Pathophysiology

2.6. Pulmonary Arterial Hypertension Diagnosis

2.7. Pulmonary Arterial Hypertension Treatment

3. Comparative Analysis of Marketed and Emerging Products

3.1. Marketed Products

3.1.1. Drug A: Company 

3.1.1.1. Product Description

3.1.1.2. Regulatory Milestones

3.1.1.3. Product Development Activities

3.1.1.3.1. General Description Table

3.1.1.4. Global Sales

3.1.1.5. Global API Manufacturers for Drug A

3.1.1.5.1. United States

3.1.1.5.2. Europe

3.1.1.5.3. China 

3.1.1.5.4. India

3.1.2. Drug B: Company

3.1.2.1. Product Description

3.1.2.2. Regulatory Milestones

3.1.2.3. Product Development Activities

3.1.2.3.1. General Description Table

3.1.2.4. Global Sales

3.1.2.5. Global API Manufacturers for Drug B

3.1.2.5.1. United States

3.1.2.5.2. Europe

3.1.2.5.3. China 

3.1.2.5.4. India

Complete details in the report

3.1.3. Emerging Therapies - Late Phase 

3.1.3.1. List of Phase III drugs for Pulmonary Arterial Hypertension

4. Appendix

5. Report Methodology

5.1. Secondary Research

5.2. Expert Panel Validation

Table 1  : List of Marketed and Emerging Products

Table 2 : Drug A Annual Global Sales from 2012-2023 (in USD million)

Table 3 : API Manufacturers for Drug A Region wise

Table 4 : API Manufacturers for Drug A for the United States

Table 5 : API Manufacturers for Drug A for Europe

Table 6 :/ API Manufacturers for Drug A for India

Table 7 : API Manufacturers for Drug A for China

Table 8 : Drug B Annual Global Sales from 2012-2023 (in USD million)

Table 9 : API Manufacturers for Drug B Region wise

Table 10 : API Manufacturers for Drug B for the United States

Table 11 : API Manufacturers for Drug B for Europe

Table 12 : API Manufacturers for Drug B for India

Table 13 : API Manufacturers for Drug B for China

Table 14 : Drug C Annual Global Sales from 2014-2023 (in USD million)

Table 15 : API Manufacturers for Drug C Region wise

Table 16 : API Manufacturers for Drug C for the United States

Table 17 : API Manufacturers for Drug C for Europe

Table 18 : API Manufacturers for Drug C for India

Table 19 : API Manufacturers for Drug C for China

Table 20 : Drug D, Annual Global Sales from 2013-2023 (in USD million)

Table 21 : API Manufacturers for Drug D Region wise

Table 22 : API Manufacturers for Drug D for the United States

Table 23 : API Manufacturers for Drug D for Europe

Table 24 : API Manufacturers for Drug D for India

Table 25 : API Manufacturers for Drug D for China

Table 26 : Drug E Annual Global Sales from 2014-2023 (in USD million)

Table 27 : API Manufacturers for Drug E Region wise

Table 28 : API Manufacturers for Drug E for the United States

Table 29 : API Manufacturers for Drug E for Europe

Table 30 : API Manufacturers for Drug E for India

Table 31 : API Manufacturers for Drug E for China

Table 32 : List of Phase III drugs for Pulmonary Arterial Hypertension


Figure 1 : Comparative Analysis of Marketed and Emerging Products

Figure 2 : Drug A, Annual Global Sales from 2012-2023 (in USD million)

Figure 3 : API Manufacturers for Drug A Region wise

Figure 4 : Drug B, Annual Global Sales from 2012-2023 (in USD million)

Figure 5 : API Manufacturers for Drug B Region wise

Figure 6 : Drug C, Annual Global Sales from 2014-2023 (in USD million)

Figure 7 : API Manufacturers for Drug C Region wise

Figure 8 : Drug D, Annual Global Sales from 2011-2023 (in USD million)

Figure 9 : API Manufacturers for Drug D Region wise

Figure 10 : Drug E, Annual Global Sales from 2014-2023 (in USD million)

Figure 11 : API Manufacturers for Drug E Region wise

Forward to Friend

Need A Quote